Table 2.
Validation metrics of whole-blood RNA signatures for discrimination of participants with PCR-confirmed SARS-CoV-2 infection at first week of PCR positivity
| AUROC | Sensitivity | Specificity | Adjusted p value | |
|---|---|---|---|---|
| IFI27 | 0·95 (0·91–0·99) | 0·84 (0·70–0·93) | 0·95 (0·85–0·98) | .. |
| Sweeney7 | 0·95 (0·91–0·99) | 0·82 (0·67–0·91) | 0·95 (0·85–0·98) | 0·85 |
| Zaas48 | 0·93 (0·88–0·98) | 0·61 (0·45–0·74) | 0·95 (0·85–0·98) | 0·088 |
| Pennisi2 | 0·91 (0·86–0·96) | 0·58 (0·42–0·72) | 0·95 (0·85–0·98) | 0·088 |
| IFI44L | 0·90 (0·84–0·96) | 0·55 (0·40–0·70) | 0·95 (0·85–0·98) | 0·039 |
| AndresTerre11 | 0·89 (0·83–0·95) | 0·55 (0·40–0·70) | 0·95 (0·85–0·98) | 0·021 |
| Henrickson16 | 0·89 (0·82–0·96) | 0·55 (0·40–0·70) | 0·93 (0·83–0·97) | 0·0093 |
| TrouilletAssant6 | 0·87 (0·80–0·94) | 0·53 (0·37–0·68) | 0·93 (0·83–0·97) | 0·008 |
| Lydon15 | 0·86 (0·79–0·94) | 0·58 (0·42–0·72) | 0·95 (0·85–0·98) | 0·0046 |
| Herberg2 | 0·84 (0·76–0·92) | 0·5 (0·35–0·65) | 0·93 (0·83–0·97) | 0·0034 |
| Sampson4 | 0·84 (0·76–0·92) | 0·5 (0·35–0·65) | 0·93 (0·83–0·97) | 0·0027 |
| Sampson10 | 0·83 (0·74–0·92) | 0·5 (0·35–0·65) | 0·95 (0·85–0·98) | 0·0021 |
| RSAD2 | 0·83 (0·74–0·91) | 0·47 (0·32–0·63) | 0·93 (0·83–0·97) | 0·0021 |
| MX1 | 0·82 (0·74–0·91) | 0·45 (0·30–0·60) | 0·95 (0·85–0·98) | 0·0017 |
| Tsalik33 | 0·79 (0·70–0·89) | 0·39 (0·26–0·55) | 0·98 (0·9–1·0) | 0·0011 |
| Lopez7 | 0·79 (0·69–0·88) | 0·37 (0·23–0·53) | 0·98 (0·9–1·0) | 0·00080 |
| IFIT3 | 0·75 (0·64–0·86) | 0·45 (0·30–0·60) | 0·93 (0·83–0·97) | 0·00027 |
| OLFM4 | 0·62 (0·51–0·74) | 0·03 (0·0–0·13) | 0·98 (0·9–1·0) | <0·0001 |
| Sweeney11 | 0·60 (0·48–0·73) | 0·16 (0·07–0·30) | 0·96 (0·88–0·99) | <0·0001 |
| Yu3 | 0·59 (0·47–0·71) | 0·05 (0·01–0·17) | 1 (0·93–1·0) | <0·0001 |
Data are point estimates (95% CIs). Includes 38 contemporaneous SARS-CoV-2-positive samples and 55 SARS-CoV-2-negative samples. Discrimination is shown as AUROC. Sensitivity and specificity are shown using predefined thresholds of 2 SDs above the mean of the uninfected control population (Z2). p values show pairwise comparisons to best performing signature with Benjamini-Hochberg adjustment (false discovery rate 0·05). Equivalent data for discrimination between test-negative controls and participants with SARS-CoV-2 infection 1 week before positive PCR test are in appendix 1 (p 7). AUROC=area under the receiver operating characteristic curve.